Endogenous anticancer mechanism: differentiation

dc.creatorWerneck, Miriam Bianchi Frontin
dc.date2018-11-29T15:04:45Z
dc.date2018-11-29T15:04:45Z
dc.date2012
dc.date.accessioned2023-09-26T22:06:58Z
dc.date.available2023-09-26T22:06:58Z
dc.identifierWERNECK, Miriam Bianchi de Frontin. Endogenous anticancer mechanism: differentiation. Frontiers in Bioscience, S4, p.1518-1538, June 2012.
dc.identifier1093-9946
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/30325
dc.identifier1093-4715
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8874951
dc.descriptionIt has been recently shown that within heterogeneous tumor masses a small population of less differentiated transformed cells has the ability to self-renew and regenerate the bulk of the tumor. Their similarities with normal stem cells in terms of gene expression patterns, proliferative capacity and surface markers rendered them the name of cancer stem-like cells (CSC), and these are thought to be the tumor initiating cells (TIC). Their limited susceptibility to classical anti-tumor therapy help explain the high incidence of cancer-treatment relapses observed in selected malignancies. Much effort is being directed towards the understanding of factors that maintain CSC survival and their self-renewal capacity, with the goal that these same signaling pathways can be harnessed for treatments that aim at inducing CSC differentiation. This review will discuss the CSC theory, its implications, potential signaling pathways responsible for maintaining their undifferentiated and pluripotent states, and new venues being explored to target these cells in modern cancer therapy.
dc.formatapplication/pdf
dc.languageeng
dc.publisherFrontiers in Bioscience
dc.rightsopen access
dc.subjectCâncer
dc.subjectmecanismo endógeno
dc.subjectTerapêutica
dc.subjectCancer
dc.subjectTherapeutic
dc.subjectendogenous mechanism
dc.titleEndogenous anticancer mechanism: differentiation
dc.typeArticle


Este ítem pertenece a la siguiente institución